Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ANNOUNCES ENGAGEMENT WITH SHANGHAI-BASED YAFO CAPITAL

Betterlife Pharma Inc. has signed an engagement agreement with Shanghai-based YAFO Capital (YAFO), as its exclusive adviser to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, Betterlife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.

Dr. Ahmad Doroudian, chief executive officer of Betterlife, commented: "We are excited to work with the YAFO team to establish partnerships for the development of BETR-001 and to bring potential non-hallucinogenic treatments for neurological disorders to the Asian region. In recent years, YAFO has successfully concluded dozens of pharma and biotech cross-border transactions."

Sean Jiang, founder and chief executive officer of YAFO, added: "We are pleased to partner with Betterlife Pharma on the advancement of BETR-001 into the Greater China region. The non-hallucinogenic profile of BETR-001 represents a highly differentiated approach in neurological therapeutics, with significant clinical and commercial potential. Through this collaboration, YAFO will leverage its deep expertise and strong pharmaceutical network to accelerate strategic partnering and development opportunities for Betterlife in Asia."

BETR-001, a potent neuroplastogen, is Betterlife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, posttraumatic stress disorder and cluster headache. Previous forms of 2-bromo-LSD has been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (Karst et al., Cephalgia 2010).

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.